Novartis has successfully completed its acquisition of Avidity Biosciences, strengthening its late-stage neuroscience pipeline and advancing its xRNA strategy. The company also announced plans to establish a new radioligand therapy manufacturing site in Texas, marking its fifth such facility in the US. Additionally, the company received a positive regulatory opinion in Europe for its drug remibrutinib for treating chronic spontaneous urticaria, potentially making it the first targeted therapy approved for this condition in the region.